A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carl Landgren, MD
University of Miami
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Miami
Miami, Florida, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Stony Brook University
Stony Brook, New York, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- Huntsman Cancer Institue
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Feb 2020
- Primary completion
- 1 Feb 2027
- Completion
- 1 Feb 2027
- Last update posted
- 24 Mar 2026
- Registered enrollment
- 310
- Registry id
- NCT04268498
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.